IN184589B - - Google Patents

Info

Publication number
IN184589B
IN184589B IN1756CA1997A IN184589B IN 184589 B IN184589 B IN 184589B IN 1756CA1997 A IN1756CA1997 A IN 1756CA1997A IN 184589 B IN184589 B IN 184589B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Victoria Marie Knepp
Steven Joseph Prestrelski
Jessica Gruber Smith
Manley Tin Fah Huang
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Priority to IN44CA2000 priority Critical patent/IN188568B/en
Publication of IN184589B publication Critical patent/IN184589B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4826—Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0026—Blood substitute; Oxygen transporting formulations; Plasma extender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
IN1756CA1997 1996-10-16 1997-09-23 IN184589B (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN44CA2000 IN188568B (fr) 1996-10-16 2000-01-28

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2816796P 1996-10-16 1996-10-16
US5292097P 1997-07-15 1997-07-15

Publications (1)

Publication Number Publication Date
IN184589B true IN184589B (fr) 2000-09-09

Family

ID=26703379

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1756CA1997 IN184589B (fr) 1996-10-16 1997-09-23

Country Status (10)

Country Link
US (3) US6264990B1 (fr)
EP (1) EP0939655B1 (fr)
JP (1) JP2002513390A (fr)
AR (1) AR008673A1 (fr)
AT (1) ATE218886T1 (fr)
AU (1) AU4821197A (fr)
CA (1) CA2264776C (fr)
DE (1) DE69713378T2 (fr)
IN (1) IN184589B (fr)
WO (1) WO1998016250A1 (fr)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN184589B (fr) * 1996-10-16 2000-09-09 Alza Corp
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
WO2001037804A2 (fr) * 1999-11-22 2001-05-31 Universal Preservation Technologies, Inc. Conservation et preparation de matieres bioactives destinees au stockage et a l'administration dans des excipients hydrophobes
US7456009B2 (en) * 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
WO2001066137A1 (fr) * 2000-03-07 2001-09-13 Merck & Co., Inc. Formulations d'adenovirus
US7153472B1 (en) 2000-11-22 2006-12-26 Quadrant Drug Delivery Limited Preservation and formulation of bioactive materials for storage and delivery in hydrophobic carriers
ATE285756T1 (de) * 2001-06-28 2005-01-15 Microchips Inc Verfahren zum hermetischen versiegeln von mikrochip-reservoir-vorrichtungen
AU2002353013A1 (en) * 2001-12-03 2003-06-17 Massachusetts Institute Of Technology Microscale lyophilization and drying methods for the stabilization of molecules
EP1534213B1 (fr) * 2002-03-13 2013-04-24 Sköld, Thomas Systemes d'administration a base aqueuse
AU2003303288B2 (en) * 2002-08-16 2006-12-07 Microchips, Inc. Controlled release device and method
AU2003278766A1 (en) * 2002-09-04 2004-03-29 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
AU2003269213B2 (en) * 2002-09-27 2008-11-13 Powderject Research Limited Nucleic acid coated particles
AU2003284018A1 (en) 2002-10-04 2004-05-04 Microchips, Inc. Medical device for neural stimulation and controlled drug delivery
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP1589901A4 (fr) 2002-12-20 2006-08-09 Generipharm Inc Injection intracutanee
WO2004091495A2 (fr) * 2003-04-09 2004-10-28 University Of Utah Research Foundation Compositions et procedes associes a la production d'erythropoietine
CA2523432C (fr) * 2003-04-25 2014-10-28 Microchips, Inc. Formulation de medicament solide, et dispositif de stockage et de distribution controlee de ce medicament
US7892205B2 (en) 2003-06-06 2011-02-22 Boston Scientific Scimed, Inc. Device and method for delivering micronized therapeutic agents in the body
ATE482650T1 (de) * 2003-11-03 2010-10-15 Microchips Inc Medizinprodukt zum messen von glucose
JP2008501037A (ja) * 2004-06-01 2008-01-17 マイクロチップス・インコーポレーテッド 医療移植片への／医療移植片からの薬物または分析物の輸送の測定および輸送の増強のためのデバイスおよび方法
WO2006015299A2 (fr) * 2004-07-30 2006-02-09 Microchips, Inc. Dispositif multi-reservoir pour la delivrance de medicament transdermique et la detection
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
US20060029551A1 (en) * 2004-08-05 2006-02-09 Kui Liu Stable particle formulations of erythropoietin receptor agonists
CA2577709C (fr) * 2004-09-01 2013-04-16 Microchips, Inc. Dispositifs a reservoir dotes de plusieurs capuchons destines a la liberation controlee ou a l'exposition de contenus de reservoir
EP2995331B1 (fr) 2004-09-10 2018-09-05 Becton, Dickinson and Company Dispositif de perfusion de reconstitution et méthode de reconstitution d'un médicament
US7488316B2 (en) 2005-01-25 2009-02-10 Microchips, Inc. Control of drug release by transient modification of local microenvironments
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (fr) 2005-02-03 2006-08-10 Alza Corporation Solutions de solvant/polymere utilisees comme vehicules de suspension
BRPI0620268B8 (pt) * 2005-12-22 2021-05-25 Oakwood Laboratories LLC composição eficaz como sistema de fornecimento para liberação controlada, seu uso, seu método de fabricação, e método para proteger um agente biologicamente ativo
ES2351527T3 (es) 2006-05-30 2011-02-07 Intarcia Therapeutics, Inc Modulador de flujo en dos piezas con conducto interno para un sistema osmótico de administración.
NZ574524A (en) 2006-08-09 2011-07-29 Intarcia Therapeutics Inc Piston assembly for positioning lumen of a reservoir for an osmotic delivery having a columnar body and a spring
LT2134353T (lt) * 2007-03-30 2017-03-27 Xisle Pharma Ventures Trust Dvifazė lipidų vezikulių kompozicija ir gimdos kaklelio displazijos gydymo būdas, skiriant intravaginaliai
EP2157967B1 (fr) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Formulations en suspension de peptides insulinotropes et leurs utilisations
US8968786B2 (en) 2007-06-22 2015-03-03 Board Of Regents, The University Of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
WO2009102467A2 (fr) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Dispositifs, formulations et méthodes d’administration de plusieurs agents bénéfiques
JP5711138B2 (ja) 2008-11-16 2015-04-30 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 高濃度の低粘度懸濁液
WO2010059253A2 (fr) * 2008-11-24 2010-05-27 Massachusets Institute Of Technology Procédés et compositions pour la délivrance localisée d'agents
LT2462246T (lt) 2009-09-28 2017-11-27 Intarcia Therapeutics, Inc Esminio stacionaraus vaisto tiekimo greitas įgyvendinimas ir (arba) nutraukimas
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
WO2011112669A1 (fr) * 2010-03-09 2011-09-15 Centocor Ortho Biotech Inc. Formulations non aqueuses de mise en suspension de viscosité réduite, à haute concentration
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
KR101656121B1 (ko) 2010-03-17 2016-09-08 노바리크 게엠베하 안압 증가를 치료하기 위한 약학 조성물
WO2012012460A1 (fr) 2010-07-19 2012-01-26 Xeris Pharmaceuticals, Inc. Formulations de glucagon stables pour le traitement de l'hypoglycémie
EP2444063A1 (fr) 2010-10-20 2012-04-25 Novaliq GmbH Compositions pharmaceutiques liquides pour l'administration de principes actifs
EP2462921A1 (fr) 2010-11-11 2012-06-13 Novaliq GmbH Compositions pharmaceutiques liquides pour le traitement d'une maladie de la chambre postérieure de l'oeil
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN105853348B (zh) 2011-03-10 2019-08-30 Xeris药物公司 肠胃外注射用稳定溶液
EP2714008B1 (fr) 2011-05-25 2016-12-14 Novaliq GmbH Composition pharmaceutique pour application sur les ongles
PL2714010T3 (pl) 2011-05-25 2017-08-31 Novaliq Gmbh Kompozycja farmaceutyczna do miejscowego stosowania oparta na semifluorowanych alkanach
KR102007057B1 (ko) 2011-10-31 2019-08-02 엑스에리스 파머수티클스, 인크. 당뇨병 치료를 위한 제형물
WO2013110621A1 (fr) 2012-01-23 2013-08-01 Novaliq Gmbh Compositions de protéine stabilisées à base d'alcanes semi-fluorés
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
CN113679697A (zh) 2012-09-12 2021-11-23 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
JP6039152B2 (ja) 2012-09-12 2016-12-07 ノバリック ゲーエムベーハー 半フッ素化アルカン組成物
EP3712142B1 (fr) 2013-01-11 2022-07-06 Corsair Pharma, Inc. Promédicaments de tréprostinil
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
AU2014228938B2 (en) * 2013-03-15 2019-05-02 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations
KR102272568B1 (ko) 2013-07-23 2021-07-05 노바리크 게엠베하 안정화 항체 조성물
US10159646B2 (en) 2013-08-12 2018-12-25 Altum-Avro Pharma Partnership Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
US8986732B2 (en) 2013-08-12 2015-03-24 Helix Biopharma Corporation Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
EP3043774B1 (fr) 2013-09-11 2020-11-04 Eagle Biologics, Inc. Formulations de protéine liquides contenant des liquides ioniques
JP7097667B2 (ja) 2013-09-27 2022-07-08 マサチューセッツ インスティテュート オブ テクノロジー 無担体生物活性タンパク質ナノ構造体
MX2016012447A (es) 2014-03-24 2017-01-06 Biogen Ma Inc Formulaciones de factor ix liofilizadas.
EP3169660A1 (fr) 2014-07-16 2017-05-24 Corsair Pharma, Inc. Composés de dérivés de tréprostinil et leurs procédés d'utilisation
EP3185932A1 (fr) 2014-08-06 2017-07-05 Xeris Pharmaceuticals, Inc. Seringues, kits et procédés pour injection intracutanée et/ou sous-cutanée de pâtes
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3200804A4 (fr) 2014-10-01 2018-04-18 Eagle Biologics, Inc. Formulations de polysaccharides et d'acides nucléiques contenant des agents réducteurs de viscosité
JP6993235B2 (ja) 2015-06-03 2022-01-13 インターシア セラピューティクス，インコーポレイティド インプラントの設置及び撤去システム
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
CN116212048A (zh) 2015-08-12 2023-06-06 麻省理工学院 纳米颗粒的细胞表面偶联
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
DE202016008738U1 (de) 2015-09-30 2019-04-09 Novaliq Gmbh Semifluorierte Verbindungen und ihre Zusammensetzungen
CN108349855B (zh) 2015-09-30 2021-07-20 诺瓦利克有限责任公司 用于眼部给药的半氟化化合物
EP3458084B1 (fr) 2016-05-16 2020-04-01 Intarcia Therapeutics, Inc Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
AU2017283480A1 (en) 2016-06-13 2019-01-24 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
ES2763121T3 (es) 2016-06-23 2020-05-27 Novaliq Gmbh Método de administración tópica
CN116172987A (zh) 2016-09-22 2023-05-30 诺瓦利克有限责任公司 用于治疗睑缘炎的药物组合物
US10813976B2 (en) 2016-09-23 2020-10-27 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
CN110678207A (zh) 2017-04-21 2020-01-10 诺瓦利克有限责任公司 碘组合物
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
CA3063324A1 (fr) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. Formulations de proteines a haute concentration ayant une viscosite reduite
JP7299166B2 (ja) 2017-06-02 2023-06-27 ゼリス ファーマシューティカルズ インコーポレイテッド 沈殿抵抗性低分子薬物製剤
EP3678701A4 (fr) 2017-09-05 2021-12-01 Torque Therapeutics, Inc. Compositions protéiques thérapeutiques et procédés de préparation et d'utilisation de celles-ci
CN111372566A (zh) 2017-09-27 2020-07-03 诺瓦利克有限责任公司 用于治疗眼部疾病的包含拉坦前列素的眼科用组合物
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
SG11202007858VA (en) 2018-03-02 2020-09-29 Novaliq Gmbh Pharmaceutical compositions comprising nebivolol
WO2019217637A1 (fr) * 2018-05-09 2019-11-14 Biomatrica, Inc. Stabilisation de protéines dans des échantillons biologiques
SG11202102820VA (en) 2018-10-12 2021-04-29 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
EP3921082A4 (fr) 2019-02-05 2022-11-02 Lindy Biosciences, Inc. Composants de culture cellulaire isolés et procédés d'isolement de ceux-ci à partir d'un milieu de culture cellulaire liquide
WO2021109979A1 (fr) * 2019-12-06 2021-06-10 Guangzhou Bioseal Biotech Co., Ltd. Pâte de thrombine fibrinogène fluide
WO2023044455A2 (fr) * 2021-09-16 2023-03-23 Team Medical Llc Stabilisation d'arn

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2342073A1 (fr) * 1976-02-27 1977-09-23 Merieux Inst Nouveau vaccin antivariolique sous forme de pate et son dispositif d'application
EP0177342A3 (fr) * 1984-10-04 1987-12-02 Genentech, Inc. Formulations orales de protéines thérapeutiques
IT8922398A0 (it) * 1989-11-16 1989-11-16 Phidea Spa Composizioni farmaceutiche ad elevato assorbimento e stabilita', comprendente una calcitonina come sostanza attiva.
US5518731A (en) * 1990-09-27 1996-05-21 Allergan, Inc. Nonaqueous fluorinated drug delivery vehicle suspensions
AU4528493A (en) 1992-06-04 1994-01-04 Regents Of The University Of California, The In vivo gene therapy with intron-free sequence of interest
ATE156361T1 (de) 1992-09-21 1997-08-15 Upjohn Co Proteinhaftige arzneimittel mit verzögerter wirkstoffabgabe
US5480914A (en) 1994-05-06 1996-01-02 Allergan, Inc. Nonaqueous thixotropic drug delivery suspensions and methods of their use
WO1996027393A1 (fr) 1995-03-07 1996-09-12 University Of Pittsburgh Formulation de poudre seche pour therapie genique
US5811406A (en) 1995-06-07 1998-09-22 Regents Of The University Of California Dry powder formulations of polynucleotide complexes
IN184589B (fr) * 1996-10-16 2000-09-09 Alza Corp

Also Published As

Publication number Publication date
DE69713378D1 (de) 2002-07-18
EP0939655B1 (fr) 2002-06-12
JP2002513390A (ja) 2002-05-08
US6730328B2 (en) 2004-05-04
WO1998016250A1 (fr) 1998-04-23
EP0939655A1 (fr) 1999-09-08
AU4821197A (en) 1998-05-11
CA2264776A1 (fr) 1998-04-23
US20040151779A1 (en) 2004-08-05
AR008673A1 (es) 2000-02-09
ATE218886T1 (de) 2002-06-15
CA2264776C (fr) 2008-11-25
US20010038859A1 (en) 2001-11-08
US6264990B1 (en) 2001-07-24
DE69713378T2 (de) 2003-01-30

Similar Documents

Publication Publication Date Title
AR026660A2 (fr)
BRPI9713914B8 (fr)
IN192215B (fr)
IN192434B (fr)
ITCA960004A0 (fr)
IN188292B (fr)
IN185387B (fr)
BR7600721U (fr)
ITMI960373A0 (fr)
BR9603859A (fr)
BR7601346U (fr)
CN3047494S (fr)
CN3047200S (fr)
CN3047919S (fr)
CN3047747S (fr)
CN3047746S (fr)
CN3047648S (fr)
CN3047647S (fr)
CN3047597S (fr)
CN3047496S (fr)
CN3047495S (fr)
EP0929398A4 (fr)
CN3047493S (fr)
CN3047348S (fr)
CN3047312S (fr)